Leucovorin Calcium Market Trends

  • Report ID: 4020
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Leucovorin Calcium Market Trends

Growth Drivers

  • Increasing Prevalence of Colon-Rectal Cancer – Leucovorin calcium is a medication commonly used as rescue therapy in combination with fluorouracil to treat colon and rectal cancer. This drug helps improve the efficacy of fluorouracil and reduce its toxicity. The increasing prevalence of colorectal cancer is a significant driver of the leucovorin market as leucovorin is an integral part of chemotherapy regimens for the disease. In 2020, 1 million cases of colon rectal cancer were recorded in the United States.
  • Growing Cancer Awareness amongst People –Increasing awareness of cancer amongst the general population is a key factor driving the market. As people become more aware of the signs and symptoms of cancer and the importance of early detection, they are more likely to see a doctor and receive appropriate treatment, including the use of leucovorin calcium.   More than 40% population gets diagnosed with cancer at an early stage.
  • Growing Prevalence of Megaloblastic Anemia – When oral medication is not an option, leucovorin calcium is used to treat megaloblastic anemia, and is further anticipated to fuel market expansion over the forecast period. Additionally, folic acid or vitamin B12 deficiency may result in megaloblastic anemia. Leucovorin calcium, aids in the restoration of normal cell division and maturation by giving the body a source of folic acid which can be used to create new red blood cells, further being a key medication in the treatment of megaloblastic anemia. Around 1.4% cases of megaloblastic anemia cases are caused by B12 deficiency.
  • Growing Prevalence of Cancer in Developed and Developing Countries – Rising presence of cancer among people situated in developed and developing countries is anticipated to propel the growth of this market in the forecast period. In developed countries, cancer rates are high owing to factors such as increased life expectancy and the adoption of unhealthy lifestyles. As developing countries undergo rapid industrialization and modernization, cancer rates are also increasing, leading to lifestyle changes and exposure to environmental risk factors. Leucovorin calcium is commonly used as a component of chemotherapy regimens for many types of cancer, including colon, stomach, and ovarian cancer. For instance, according to studies 225,800 new cases of cancer were recorded in Canada in 2020. 

Challenges

  • Non-compatibility with other Drugs – Leucovorin calcium has some compatibility problems with various drugs such as capecitabine, and cotrimoxazole and also, leucovorin calcium reacts with breastfeeding, pregnant women, children, people with seizer problems, and geriatric population undergoing this medication must be kept under special monitoring. This factor might restrict the market to growth in the forecast period.
  • High Cost Associated with Cancer Treatment
  • Side Effects of Cancer Treatment Drugs

Leucovorin Calcium Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

16.2%

Base Year Market Size (2023)

USD 23.24 Million

Forecast Year Market Size (2036)

USD 163.65 Million

Regional Synopsis

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4020
  • Published Date: Jul 25, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of leucovorin calcium is assessed at USD 26.63 Million.

The leucovorin calcium market size was valued at USD 23.24 Million in 2023 and is likely to reach USD 163.65 Million by the end of 2036, registering around 16.2% CAGR during the forecast period i.e., between 2024-2036. The increasing prevalence of colorectal cancer and rising cancer awareness are some of the major factors anticipated to drive the market growth.

North America industry is expected to have the highest growth through 2036, owing to presence of major pharmaceutical companies in the region.

Exelixis Inc., PromoCell GmbH, Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Bayer AG, Abbott Laboratories, Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample